Physician profile
Peter D Riley
NPI 1942260237
$985.18
in general payments reported to CMS, 2019-2025
15 companies · $84.58 in 2025
The $84.58 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.24 · 2020: $45.42 · 2021: $312 · 2022: $182 · 2023: $94.83 · 2024: $176 · 2025: $84.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $180.22 | 2021 | |
| Abbott Laboratories | $143.40 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $112.22 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $108.04 | 2020-2024 | Trelegy Ellipta, Nucala |
| Inspire Medical Systems, INC. | $80.73 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $71.92 | 2023-2024 | Dupixent |
| Harmony Biosciences LLC | $50.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.79 | 2019-2023 | Ofev |
| Jazz Pharmaceuticals INC. | $41.86 | 2019-2021 | |
| Grifols USA, LLC | $35.86 | 2019-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $27.78 | 2025 | |
| Itamar Medical INC | $25.95 | 2025 | Watchpatone |
| United Therapeutics Corporation | $22.26 | 2024 | Tyvaso |
| Mylan Specialty L.P. | $21.32 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.